Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasted to Post Q1 2025 Earnings of ($0.36) Per Share

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Foghorn Therapeutics in a report issued on Monday, May 6th. Wedbush analyst R. Driscoll anticipates that the company will post earnings of ($0.36) per share for the quarter. Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($2.05) per share. Wedbush also issued estimates for Foghorn Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.30) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last posted its earnings results on Thursday, March 7th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.22. The firm had revenue of $5.77 million during the quarter, compared to the consensus estimate of $4.91 million.

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Foghorn Therapeutics in a report on Tuesday.

Foghorn Therapeutics Stock Up 6.2 %

Shares of NASDAQ FHTX opened at $5.98 on Wednesday. The stock has a market cap of $254.57 million, a P/E ratio of -2.39 and a beta of 3.15. The firm’s 50-day simple moving average is $6.41 and its 200 day simple moving average is $5.35. Foghorn Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $9.97.

Hedge Funds Weigh In On Foghorn Therapeutics

Several large investors have recently made changes to their positions in FHTX. Raymond James & Associates raised its stake in shares of Foghorn Therapeutics by 19.8% in the third quarter. Raymond James & Associates now owns 1,426,226 shares of the company’s stock worth $7,131,000 after acquiring an additional 235,237 shares during the last quarter. Panagora Asset Management Inc. bought a new position in Foghorn Therapeutics in the 3rd quarter worth approximately $173,000. Exchange Traded Concepts LLC lifted its holdings in Foghorn Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 21,535 shares of the company’s stock worth $139,000 after buying an additional 5,460 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Foghorn Therapeutics by 788.1% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,000 shares of the company’s stock worth $32,000 after buying an additional 4,437 shares in the last quarter. Finally, Alta Wealth Advisors LLC bought a new position in Foghorn Therapeutics in the 4th quarter valued at $194,000. Institutional investors own 61.55% of the company’s stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.